Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trade groups on bird flu

This article was originally published in The Tan Sheet

Executive Summary

"Marketers and retailers of dietary supplements are urged to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu," a coalition of supplement industry trade groups announces in a joint advisory issued Nov. 18. The American Herbal Products Association, Consumer Healthcare Products Association, Council for Responsible Nutrition and National Nutritional Foods Association "encourag[e] consumers to use caution should they encounter products which claim to treat or prevent the avian flu" and note that "federal law and regulations do not allow any dietary supplement product" to make such claims. Although supplements can enhance general immune function, therapies for prevention or treatment of avian flu "should only be recommended by qualified healthcare professionals or public health authorities," the groups conclude...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS098855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel